- Home
- NAAS vs CPHI Comparison
NAAS vs CPHI Comparison
Compare NAAS & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAAS | CPHI |
|---|---|---|
| Founded | 2019 | N/A |
| Country | China | China |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.8M | 31.2M |
| IPO Year | 2017 | 2008 |
Fundamental Metrics
Financial Performance| Metric | NAAS | CPHI |
|---|---|---|
| Price | $3.09 | $0.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.3K | ★ 19.6K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,144,268.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.49 | $0.38 |
| 52 Week High | $4.54 | $2.00 |
Technical Indicators
Market Signals| Indicator | NAAS | CPHI |
|---|---|---|
| Relative Strength Index (RSI) | 57.35 | 40.75 |
| Support Level | $2.94 | $0.54 |
| Resistance Level | $3.19 | $0.68 |
| Average True Range (ATR) | 0.13 | 0.10 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 71.79 | 0.90 |
Price Performance
Historical ComparisonAbout NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
About CPHI China Pharma Holdings Inc.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.